This article first appeared on GuruFocus .
-
Revenue:Increased from INR 1,085 crores to INR 2,300 crores in FY25-26.
-
Liquid Assets:Tripled from INR 928 crores to INR 2,726 crores.
-
Free Cash Flow:Tripled from INR 470 crores to INR 1,470 crores.
-
EBITDA, PBT, and PAT:Increased by 2.5 times over the last five years.
-
Net Worth:Expanded by INR 745 crores to INR 3,631 crores, a 26% increase in one year.
-
Cash and Liquid Assets:INR 1,471 crores in cash and INR 2,726 crores in liquid assets.
-
Cash Conversion:Cash inflow of INR 523 crores, representing 80% of PAT.
-
Profit Growth:20% growth, ahead of revenue growth of 13%.
-
R&D Spend:Crossed INR 100 crores, approximately 5% of turnover.
-
CapEx:INR 238 crores spent last year, with ongoing projects totaling INR 1,000 crores.
-
Fixed Asset Turnover Ratio:3.91x.
-
Inventory Potential:INR 900 crores in sales potential from inventory held.
-
Warning! GuruFocus has detected 1 Warning Sign with BOM:524742.
-
Is BOM:524742 fairly valued? Test your thesis with our free DCF calculator.
Release Date: May 14, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Caplin Point Laboratories Ltd ( BOM:524742 ) reported a significant increase in revenue, doubling from INR1,085 crores to INR2,300 crores over the past five years.
-
The company has tripled its liquid assets from INR928 crores to INR2,726 crores, showcasing strong financial health.
-
Caplin Point Laboratories Ltd ( BOM:524742 ) has made substantial investments in CapEx, amounting to INR900 crores over the last five years, indicating a commitment to growth and expansion.
-
The company has received approvals for 10 ANDAs in the last four quarters and acquired another 15 ANDAs, expanding its product portfolio significantly.
-
Caplin Point Laboratories Ltd ( BOM:524742 ) is focusing on R&D for hormone injection and inhaler areas, which are unique in regulated markets, indicating a strategic focus on innovation.
Negative Points
-
Receivables have grown materially ahead of revenue growth, raising concerns about cash flow management.
-
The company faces challenges related to currency swings and energy unpredictability, which could impact operational costs.
-
There is a dependency on outsourcing for the Latin American market, which could limit top-line growth due to capacity constraints.
-
Despite strong financials, the company acknowledges that the best growth period is expected in the next 3 to 5 years, indicating a longer wait for peak performance.
-
The company is still in the process of completing its infrastructure expansion, which may delay immediate benefits from new facilities and product lines.
Q & A Highlights
Q: How does Caplin Point Laboratories plan to prioritize between inorganic opportunities, incremental CapEx, and higher shareholder payout given the growing cash generation? A: Chingelput Paarthipan, Non-Executive Chairman, stated that the company is focusing on meaningful acquisitions, particularly in buying ANDAs and potentially acquiring a distribution company in Latin America. The completion of facilities for injectables is a priority, aiming to expand in the US and other major markets. The company is also concentrating on R&D for complex products and increasing registrations in larger geographies.
Q: Why have receivables grown materially ahead of revenue growth? Is this a timing-related issue? A: D. Muralidharan, CFO, explained that the increase in receivables is partly due to foreign exchange reserves impacting the net worth and receivables. Additionally, a large tender in El Salvador contributed to the increase, with receivables expected to be collected by the end of Q2.
Q: What is the outlook for FY27 in terms of top-line growth and margins? A: Chingelput Paarthipan expressed confidence in continued strong performance, noting that the best period for Caplin Point is expected in the next 3 to 5 years. While specific quarterly or yearly guidance was not provided, the company anticipates significant growth, especially with potential inorganic opportunities.
Q: What has led to the high revenue growth in the LatAm and Africa business, excluding the US? A: Chingelput Paarthipan mentioned that market fluctuations and strategic decisions to keep goods in warehouses have contributed to growth. The company is focusing on completing registrations in markets like Mexico and starting business in Chile, which will enhance growth over time.
Q: Can Caplin Point maintain a double-digit revenue growth rate and PAT margin between 25% to 29% consistently in the coming years? A: Vivek Partheeban, Non-Executive Vice Chairman, affirmed confidence in maintaining strong performance, noting that the business is transitioning to a phase of scaling and growth. Despite some segments not yet breaking even, the company expects to sustain or improve current margins over the next 18 to 24 months.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
